These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9797577)

  • 21. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
    Torres RJ; Puig JG
    Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of gout.
    Perez-Ruiz F; Schlesinger N
    Scand J Rheumatol; 2008; 37(2):81-9. PubMed ID: 18415763
    [No Abstract]   [Full Text] [Related]  

  • 24. Serum urate during bouts of acute gouty arthritis.
    Schlesinger N; Baker DG; Schumacher HR
    J Rheumatol; 1997 Nov; 24(11):2265-6. PubMed ID: 9375898
    [No Abstract]   [Full Text] [Related]  

  • 25. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report.
    Wipfler-Freibmuth E; Dejaco C; Duftner C; Gaugg M; Kriessmayr-Lungkofler M; Schirmer M
    Clin Exp Rheumatol; 2009; 27(4):658-60. PubMed ID: 19772802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of gout after transplantation.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Duruelo J
    Br J Rheumatol; 1998 May; 37(5):580. PubMed ID: 9651090
    [No Abstract]   [Full Text] [Related]  

  • 28. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
    Faruque LI; Ehteshami-Afshar A; Wiebe N; Tjosvold L; Homik J; Tonelli M
    Semin Arthritis Rheum; 2013 Dec; 43(3):367-75. PubMed ID: 24326033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of gout].
    Dudler J; Gerster JC
    Rev Med Suisse Romande; 2000 Oct; 120(10):781-6. PubMed ID: 11109907
    [No Abstract]   [Full Text] [Related]  

  • 32. Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.
    Takahashi S; Yamamoto T; Moriwaki Y; Tsutsumi Z; Yamakita J; Higashino K
    Metabolism; 1998 Mar; 47(3):336-8. PubMed ID: 9500573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hyperuricemia/gout. Main symptoms of arthropathy. Severe acute joint pain, redness, inflammation].
    Kolyvanos Naumann U; Suter PM; Käser L; Vetter W
    Praxis (Bern 1994); 2005 Apr; 94(14):543-8; quiz 549. PubMed ID: 15849976
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical practice. Gout.
    Neogi T
    N Engl J Med; 2011 Feb; 364(5):443-52. PubMed ID: 21288096
    [No Abstract]   [Full Text] [Related]  

  • 37. Serum urate during acute gout.
    Schlesinger N; Norquist JM; Watson DJ
    J Rheumatol; 2009 Jun; 36(6):1287-9. PubMed ID: 19369457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of uric acid in scalp hair for non-invasive evaluation of uricemic controls in hyperuricemia.
    Kobayashi K; Morioka Y; Isaka Y; Tozawa T
    Biol Pharm Bull; 1998 Apr; 21(4):398-400. PubMed ID: 9586580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.